[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Top Stock Alerts [@TopStockAlerts1](/creator/twitter/TopStockAlerts1) on x 118.6K followers Created: 2025-07-18 13:27:59 UTC $SRPT Sarepta Therapeutics' stock crashed XX% in premarket trading Friday, erasing all gains tied to its recent restructuring plans. The drop followed the death of a third patient, a 51-year-old man with limb-girdle muscular dystrophy (LGMD), who died of acute liver failure after receiving the company’s experimental gene therapy. This follows the deaths of two teenagers who died of similar liver complications after treatment with Sarepta’s approved gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD). While Sarepta announced restructuring measures on Wednesday, including layoffs and plans to cut $XXX million in annual costs, it did not disclose the third death during its call with analysts or issue a press release. The stock had gained XXXX% on Thursday after the company revealed it would pause most gene therapy development, including the one tied to the recent death XXXXX engagements  **Related Topics** [chapter 11](/topic/chapter-11) [$srpt](/topic/$srpt) [sarepta therapeutics inc](/topic/sarepta-therapeutics-inc) [stocks healthcare](/topic/stocks-healthcare) [Post Link](https://x.com/TopStockAlerts1/status/1946200278950429176)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Top Stock Alerts @TopStockAlerts1 on x 118.6K followers
Created: 2025-07-18 13:27:59 UTC
$SRPT Sarepta Therapeutics' stock crashed XX% in premarket trading Friday, erasing all gains tied to its recent restructuring plans. The drop followed the death of a third patient, a 51-year-old man with limb-girdle muscular dystrophy (LGMD), who died of acute liver failure after receiving the company’s experimental gene therapy. This follows the deaths of two teenagers who died of similar liver complications after treatment with Sarepta’s approved gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD). While Sarepta announced restructuring measures on Wednesday, including layoffs and plans to cut $XXX million in annual costs, it did not disclose the third death during its call with analysts or issue a press release. The stock had gained XXXX% on Thursday after the company revealed it would pause most gene therapy development, including the one tied to the recent death
XXXXX engagements
Related Topics chapter 11 $srpt sarepta therapeutics inc stocks healthcare